ImmuPharma (LON:IMM) Trading Up 28.6% - Still a Buy?

Key Points

• ImmuPharma's share price surged by 28.6% on Tuesday, closing at GBX 11.30 ($0.15) compared to the previous close of GBX 8.79 ($0.12), with almost 17 million shares changing hands.
• The company's market capitalization stands at £56.47 million, but it reports a highly negative PE ratio of -1,269.66 and a negative return on equity of 131.41%.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, specifically targeting Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price rose 28.6% during trading on Tuesday . The company traded as high as GBX 12 ($0.16) and last traded at GBX 11.30 ($0.15). Approximately 17,007,168 shares traded hands during trading, an increase of 97% from the average daily volume of 8,614,648 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Trading Up 28.6%

The stock's 50-day moving average is GBX 5.49 and its two-hundred day moving average is GBX 3.64. The company has a market capitalization of £56.47 million, a PE ratio of -1,269.66 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.